If you are not happy with the results below please do another search
The announcement comes following the October 2023 acquisition of Healthware Group, an agency and innovation consultancy headquartered in Salerno, Italy. The new affiliate will operate from multiple offices across Italy, Finland, the United Kingdom and the United States, focused on innovation, transformation and client delight.
U.S. gene sequencing company Illumina’s plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago.
The European Medicines Agency announced on Friday that it has found no causal association between GLP-1 receptor agonists—a popular class of weight-loss treatments that include Novo Nordisk’s Wegovy (semaglutide)—and the risks of suicidal thoughts and actions.
A Florida judge on Tuesday dismissed Eli Lilly’s case against a compounding pharmacy, finding that the drugmaker cannot use state law in its campaign against reformulated versions of the company’s top-selling weight-loss and diabetes medication tirzepatide.
The FDA on Thursday greenlit the label expansion of AstraZeneca’s subcutaneous IL-5 receptor blocker Fasenra (benralizumab), which can now be used as an add-on maintenance treatment for severe eosinophilic asthma in children six to 11 years of age.
Fujifilm Corporation on Thursday announced that it is investing $1.2 billon to bolster its end-to-end manufacturing capacity at the company’s Holly Springs, North Carolina site.
Deaths caused by the mosquito-borne dengue disease have more than tripled in Peru so far this year, according to data from the South American nation’s government, which is redoubling efforts to contain an epidemic that has hit poor areas the hardest.
Novartis announced Thursday an exclusive strategic partnership with Arvinas to advance an oral protein degrader for prostate cancer, while also announcing the tender offer for its $2.9 billion acquisition of MorphoSys has commenced.
The U.S. Department of Justice announced Wednesday it has filed a False Claims Act complaint against Regeneron Pharmaceuticals, alleging that the company “fraudulently inflated Medicare reimbursement rates” for its eye therapy Eylea (aflibercept).
Many pharmaceutical companies listed strategic objectives for 2024 that included solving for health inequities, clearly positioned within pillars that focused on improving or increasing the value of their products. For one reason or another, many of those objectives were set aside as planning commenced in the new year, leaving this crushing challenge to our society unaddressed.